Forsta AP Fonden Increases Holdings in Cencora, Inc. $COR

Forsta AP Fonden raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 31.6% in the 2nd quarter, HoldingsChannel reports. The fund owned 83,370 shares of the company’s stock after buying an additional 20,000 shares during the quarter. Forsta AP Fonden’s holdings in Cencora were worth $24,998,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CWM LLC raised its stake in Cencora by 0.9% during the 1st quarter. CWM LLC now owns 10,217 shares of the company’s stock worth $2,841,000 after acquiring an additional 95 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Cencora by 3.9% during the first quarter. Signaturefd LLC now owns 3,755 shares of the company’s stock worth $1,044,000 after purchasing an additional 141 shares during the last quarter. Apollon Wealth Management LLC increased its position in shares of Cencora by 11.1% during the first quarter. Apollon Wealth Management LLC now owns 5,949 shares of the company’s stock worth $1,654,000 after purchasing an additional 596 shares in the last quarter. Sage Mountain Advisors LLC purchased a new stake in shares of Cencora in the 1st quarter valued at about $282,000. Finally, Larson Financial Group LLC boosted its position in shares of Cencora by 31.9% in the 1st quarter. Larson Financial Group LLC now owns 2,276 shares of the company’s stock valued at $633,000 after purchasing an additional 550 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Mizuho lifted their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company lifted their target price on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday. JPMorgan Chase & Co. increased their price target on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Finally, Morgan Stanley set a $330.00 target price on shares of Cencora and gave the company an “equal weight” rating in a report on Wednesday, July 16th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus target price of $371.09.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 41,544 shares of company stock valued at $12,230,941 over the last three months. Insiders own 10.80% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $363.75 on Thursday. The stock has a market capitalization of $70.52 billion, a P/E ratio of 37.42, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $366.17. The company’s fifty day moving average is $318.52 and its two-hundred day moving average is $301.12.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.